Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 21

1559P - PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis

Date

21 Oct 2023

Session

Poster session 21

Topics

Tumour Site

Oesophageal Cancer

Presenters

Manavi Sachdeva

Citation

Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10.1016/S0923-7534(23)01930-0

Authors

M. Sachdeva1, J.J. Zhao2, K.X. Zhu3, D. Ting Wei Yap4, N. Zhun Hong Wong5, N.K. Barr6, R. Sundar7

Author affiliations

  • 1 Medical Oncology, NCIS - National University Cancer Institute Singapore, 119074 - Singapore/SG
  • 2 Internal Medicine, NUS - National University of Singapore, 119077 - Singapore/SG
  • 3 Department Of Biomedical Informatics, National University of Singapore (NUS) - Faculty of Science, 117543 - Singapore/SG
  • 4 Yong Loo Lin School Of Medicine, NUS - National University of Singapore, 119077 - Singapore/SG
  • 5 Yong Loo Lin School Of Medicine, NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), 117597 - Singapore/SG
  • 6 Nuhs, NUS - National University of Singapore, 119077 - Singapore/SG
  • 7 Haematology-oncology, NUHS - National University Health System, 119228 - Singapore/SG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1559P

Background

Prognosis for aESCC (advanced esophageal squamous cell carcinoma) remains poor. Programmed death-ligand 1 (PD-L1) expression is a well-established positive predictive biomarker for response to immunotherapy in aESCC. However, the association between PD-L1 and response to chemotherapy alone remains unclear. This study aims to determine the prognostic significance of PD-L1 expression in patients treated with first-line chemotherapy alone in aESCC.

Methods

First-line phase III randomized trials that included PD-L1 expression as a biomarker in aESCC were extracted after a systematic search of Embase and PubMed from inception until September 24, 2022. Only trials that reported PD-L1 stratified Kaplan-Meier (KM) curves of chemotherapy arms were included. A graphical reconstructive algorithm was used to estimate time-to-event outcomes from reported KM plots in all overall and reported subgroup cohorts. Where unavailable, KMSubtraction was utilized to derive KM plots of unreported PD-L1 subgroups. Thereafter, individual patient data meta-analysis was conducted. Survival analyses for overall and progression-free survival (OS, PFS) were conducted with Cox proportional hazards models with a shared-frailty term incorporated to account for inter-study differences.

Results

Chemotherapy arms from 5 randomized phase III trials - CheckMate-648, ESCORT-first, KEYNOTE-590, RATIONALE306 and ORIENT-15 – comprising 1,517 patients were included in the OS analysis. Compared to PD-L1 low expressing tumors, patients with PD-L1 high expressing tumors were at a significantly higher risk of mortality (PD-L1 high [n=769] vs PD-L1 low [n=748], HR=1.152, 95%-CI: 1.018 – 1.305, p=0.025). Three trials – CheckMate-648, ESCORT-first and ORIENT-15 – comprising 949 patients treated with chemotherapy alone were included in the PFS analysis. Likewise, patients with PD-L1 high expressing tumors were at a higher risk of tumor progression, although this was not significant (PD-L1-high [n=513] vs PD-L1-low [n=436], HR=1.076, 95%-CI: 0.923 - 1.253, p=0.35).

Conclusions

Our study found PD-L1 expression is a negative predictor of overall survival in aESCC treated with first-line chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

R. Sundar: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, GSK, DKSH, Astellas; Financial Interests, Personal, Invited Speaker: MSD, Eli Lilly, BMS, Roche, Taiho, AstraZeneca, DKSH, Ipsen; Financial Interests, Personal and Institutional, Local PI: MSD, Taiho, BMS, Novartis; Financial Interests, Personal, Stocks/Shares: Teladoc; Financial Interests, Institutional, Advisory Board: Paxman Coolers; Non-Financial Interests, Advisory Role: Paxman Coolers; Non-Financial Interests, Principal Investigator: MSD, Natera. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.